rs776443981
Positions:
Variant summary
Our verdict is Likely pathogenic. Variant got 6 ACMG points: 6P and 0B. PM1PM2PP3_Moderate
The NM_001042432.2(CLN3):āc.1225A>Gā(p.Met409Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000198 in 1,613,748 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000013 ( 0 hom., cov: 32)
Exomes š: 0.000021 ( 0 hom. )
Consequence
CLN3
NM_001042432.2 missense
NM_001042432.2 missense
Scores
8
8
3
Clinical Significance
Conservation
PhyloP100: 3.93
Genes affected
CLN3 (HGNC:2074): (CLN3 lysosomal/endosomal transmembrane protein, battenin) This gene encodes a protein that is involved in lysosomal function. Mutations in this, as well as other neuronal ceroid-lipofuscinosis (CLN) genes, cause neurodegenerative diseases commonly known as Batten disease or collectively known as neuronal ceroid lipofuscinoses (NCLs). Many alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_pathogenic. Variant got 6 ACMG points.
PM1
In a mutagenesis_site Does not affect lysosomal targeting; when associated with A-419. Loss of lysosomal targeting; when associated with A-253 and A-254. Loss of lysosomal targeting; when associated with 242-A--A-244 and A-419. Does not affect interaction with CLN5; when associated with A-419. Does not affect interaction with CLN5; when associated with A-253; A-254 and A-419. Loss of lysosomal targeting; when associated with A-253; A-254 and A-419. Loss of lysosomal localization in AP3D1 or AP1G1 deficient cells; when associated with A-419. (size 0) in uniprot entity CLN3_HUMAN
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.904
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CLN3 | NM_001042432.2 | c.1225A>G | p.Met409Val | missense_variant | 16/16 | ENST00000636147.2 | NP_001035897.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CLN3 | ENST00000636147.2 | c.1225A>G | p.Met409Val | missense_variant | 16/16 | 1 | NM_001042432.2 | ENSP00000490105.1 | ||
ENSG00000261832 | ENST00000637378.1 | c.228+4497A>G | intron_variant | 5 | ENSP00000490831.1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151996Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
2
AN:
151996
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000399 AC: 10AN: 250566Hom.: 0 AF XY: 0.0000738 AC XY: 10AN XY: 135508
GnomAD3 exomes
AF:
AC:
10
AN:
250566
Hom.:
AF XY:
AC XY:
10
AN XY:
135508
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000205 AC: 30AN: 1461752Hom.: 0 Cov.: 31 AF XY: 0.0000289 AC XY: 21AN XY: 727168
GnomAD4 exome
AF:
AC:
30
AN:
1461752
Hom.:
Cov.:
31
AF XY:
AC XY:
21
AN XY:
727168
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151996Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74236
GnomAD4 genome
AF:
AC:
2
AN:
151996
Hom.:
Cov.:
32
AF XY:
AC XY:
0
AN XY:
74236
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
6
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 31, 2014 | p.Met409Val (ATG>GTG): c.1225 A>G in exon 16 of the CLN3 gene (NM_001042432.1). The Met409Val missense change has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The Met409Val variant alters a well conserved region across species in the cytoplasmic C-terminus region of the CLN3 protein and a nearby missense mutation has been reported in this region of the CLN3 protein in association with neuronal ceroid lipofuscinosis (Kousi et al., 2012). In addition, in silico analysis predicts this variant is probably damaging to the protein structure/function. However, this variant is a conservative substitution of one uncharged non-polar amino acid for another. Therefore, based on the currently available information, it is unclear whether Met409Val is a disease-causing mutation or a rare benign variant. The variant is found in EPILEPSY panel(s). - |
Neuronal ceroid lipofuscinosis Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 18, 2022 | This sequence change replaces methionine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 409 of the CLN3 protein (p.Met409Val). This variant is present in population databases (rs776443981, gnomAD 0.01%). This missense change has been observed in individual(s) with retinitis pigmentosa (PMID: 33507216). ClinVar contains an entry for this variant (Variation ID: 205101). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Neuronal ceroid lipofuscinosis 3 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Sep 05, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;.;.;D;.;.;D;D;D;.;D;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
.;.;D;.;.;D;D;D;.;D;D;D;.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
M;M;.;.;.;.;.;.;M;.;.;.;.;.
PrimateAI
Benign
T
PROVEAN
Uncertain
.;D;.;.;D;D;D;.;D;.;D;.;.;D
REVEL
Pathogenic
Sift
Uncertain
.;D;.;.;D;D;D;.;D;.;D;.;.;D
Sift4G
Uncertain
.;.;T;.;D;D;D;.;D;.;D;.;.;.
Polyphen
D;D;.;.;D;.;.;.;D;D;D;P;.;D
Vest4
0.49, 0.66, 0.64, 0.67, 0.66, 0.73
MutPred
Loss of disorder (P = 0.1129);Loss of disorder (P = 0.1129);.;.;.;.;.;.;Loss of disorder (P = 0.1129);.;.;.;.;.;
MVP
0.91
MPC
0.52
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at